Edwards Lifesciences reports Q2 sales of $1.74 billion
Edwards Lifesciences reported a quarterly sales increase of 13.6% driven by TAVR and TMTT. The company updated its sales growth outlook to 10-11%.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day